Ironically, these findings are coming to light in an era when their relevance is diminishing, with the advent of drugs (flozins and GLP1RAs) which can be safely used below GFR 30, and which also have evidence of clinical outcome benefits
GLP-1 receptors are found in several brain regions, including: The ventral tegmental area (VTA) The nucleus accumbens The prefrontal cortex When activated by GLP-1, these receptors appear to reduce the release of dopamine in response to addictive substances
With embedded MRI contrast agents, they enable simultaneous imaging and localized therapy by targeting GLP-1R expressed on plaque-associated smooth muscle cells and macrophages
It supports muscle maintenance, promotes satiety, and regulates metabolism
Patients with obesity or who are overweight lost up to 12.3% of their weight compared with placebo at week 28 in the ongoing phase two study